Corbus Pharmaceuticals Holdings Inc. announced today that an abstract on updated clinical data from its Phase 1/2 clinical study of CRB-701 (SYS6002) has been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025. The congress is scheduled to be held from October 17-21, 2025, in Berlin, Germany. This presentation will provide further insights into the dose optimization and expansion phases of the study.
The abstract is titled "A Phase 1/2 Study of CRB-701 (SYS6002), a Next-Generation Nectin-4 Targeting ADC, in Patients with Advanced Solid Tumors: Dose Optimization and Expansion Data." This upcoming presentation is a significant catalyst for the company, as it will reveal more comprehensive clinical data for its lead oncology asset. Investors and the medical community will be closely watching for these results.
The data to be presented will build upon the encouraging safety and efficacy signals previously reported from the dose escalation phase of the CRB-701 Western study. The ESMO Congress is a major international oncology conference, providing a prominent platform for Corbus to showcase the progress of CRB-701 in patients with advanced solid tumors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.